Primary genetic markers such as IDH mutations, CDKN2A deletions, 1p/19q‐codeletions, H3F3A alterations, MGMT promoter methylation status and EGFR amplification are used in the glioma classification system.20, 21. This evidence concerns the gene MGMT and central nervous system cancer.